LivingGLP1
Study S002265

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT05048719
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
DOUBLE
Status
COMPLETED
Enrollment
383
Start
2021-09-15
Primary completion
2022-09-30
Lead sponsor
Eli Lilly and Company
Conditions
Type 2 Diabetes
Interventions
DRUG:LY3502970; DRUG:Dulaglutide; DRUG:Placebo
Results posted
TRUE
Individual participant data sharing
YES
Secondary identifiers
OTHER:J2A-MC-GZGE; EUDRACT_NUMBER:2021-002806-29

Registered primary outcomes

  • Change From Baseline in HbA1c in LY3502970 as Compared to Placebo [Baseline, Week 26]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0004295Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
Wharton S, Cardiovascular diabetology
2025Other trialPMID 40481478DOIcites ClinicalTrials.gov:NCT05048719; registry reference DERIVED:40481478
R0008897Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Frias JP, Lancet (London, England)
2023Randomized trialPMID 37369232DOIcites ClinicalTrials.gov:NCT05048719; registry reference DERIVED:37369232
R0016965The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.
Tommerdahl KL, Clinical journal of the American Society of Nephrology : CJASN
2022Randomized trialPMID 35396319DOIcites ClinicalTrials.gov:NCT05048719